Maridea Wealth Management LLC Raises Stock Holdings in Bristol Myers Squibb Company $BMY

Maridea Wealth Management LLC raised its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 179.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 13,172 shares of the biopharmaceutical company’s stock after buying an additional 8,462 shares during the quarter. Maridea Wealth Management LLC’s holdings in Bristol Myers Squibb were worth $574,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Darwin Wealth Management LLC purchased a new position in shares of Bristol Myers Squibb during the second quarter valued at approximately $25,000. Harbor Capital Advisors Inc. boosted its stake in Bristol Myers Squibb by 107.2% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 313 shares in the last quarter. Total Investment Management Inc. purchased a new stake in Bristol Myers Squibb during the 2nd quarter valued at about $38,000. Twin Peaks Wealth Advisors LLC bought a new stake in Bristol Myers Squibb during the 2nd quarter valued at about $40,000. Finally, Mark Sheptoff Financial Planning LLC raised its holdings in Bristol Myers Squibb by 233.3% in the second quarter. Mark Sheptoff Financial Planning LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $46,000 after buying an additional 700 shares during the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Bank of America upgraded shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and increased their price target for the company from $52.00 to $61.00 in a report on Monday, December 15th. Truist Financial set a $65.00 target price on Bristol Myers Squibb in a report on Wednesday, December 3rd. BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 17th. HSBC reaffirmed a “hold” rating and set a $53.00 price objective on shares of Bristol Myers Squibb in a research report on Wednesday, December 10th. Finally, Cantor Fitzgerald reissued a “neutral” rating on shares of Bristol Myers Squibb in a research report on Monday, November 24th. Eight equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $59.20.

Bristol Myers Squibb Stock Performance

Shares of NYSE BMY opened at $59.82 on Thursday. The firm has a fifty day moving average price of $55.87 and a 200-day moving average price of $49.79. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $63.33. The stock has a market cap of $121.83 billion, a PE ratio of 17.34, a price-to-earnings-growth ratio of 0.17 and a beta of 0.29. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The business had revenue of $12.50 billion during the quarter, compared to analysts’ expectations of $12.24 billion. During the same period in the prior year, the firm posted $1.67 earnings per share. The firm’s revenue for the quarter was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd were given a dividend of $0.63 per share. The ex-dividend date was Friday, January 2nd. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 73.04%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.